# Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

> **NCT03663933** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 71 (actual)

## Conditions studied

- Lymphoproliferative Disorders
- Autoimmune Lymphoproliferative
- Primary T-cell Immunodeficiency Disorders
- Immune System Diseases
- Common Variable Immunodeficiency

## Interventions

- **DRUG:** e-ATG
- **PROCEDURE:** Immunosuppression Only Conditioning
- **PROCEDURE:** Reduced Intensity Conditioning
- **DRUG:** GVHD Prophylaxis
- **PROCEDURE:** Allogeneic HSC
- **DRUG:** Bisulfan
- **DRUG:** Prednisone
- **DRUG:** Cyclophosphamide
- **DRUG:** MMF
- **DRUG:** Mesna
- **DRUG:** Tacrolimus
- **DRUG:** Pentostatin
- **DIAGNOSTIC_TEST:** PFTs
- **DIAGNOSTIC_TEST:** DEXA
- **PROCEDURE:** Bone Marrow Aspirate & Biopsy
- **DIAGNOSTIC_TEST:** EKG
- **DIAGNOSTIC_TEST:** 2D ECHO

## Key facts

- **NCT ID:** NCT03663933
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-04
- **Primary completion:** 2025-04-03
- **Final completion:** 2030-04-03
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03663933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03663933, "Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03663933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*